

Curriculum Vitae
<p>Carol Murphy Researcher A', Biomedical Research Institute, Foundation for Research & Technology Hellas (BRI-FORTH), Ioannina, Greece</p> <p>Tel: +30 26510 07815, 2811 392164 E-mail: carol_murphy@bri.forth.gr https://www.bri.forth.gr/bri-people/en/murphy-fotsis-laboratory https://www.bri.forth.gr/en/research-en/item/90-carol-murphy</p>
Positions & Employment
2021- : Researcher A'. Director of Research at BRI-FORTH, Ioannina, Greece
2003-2021: Researcher B' at BRI-FORTH, Ioannina, Greece
2015-2017: Senior lecturer, School of Biosciences, University of Birmingham, UK
2001-2003: Researcher C' at BRI-FORTH, Ioannina, Greece
1997-2001: Researcher in Depart. Biol. Chem., University of Ioannina, Medical School
1996-1997: EU Senior Researcher award for research in University of Ioannina
1993-1996: Postdoctoral researcher at EMBL in the lab of Marino Zerial
1989-1993: Postdoctoral researcher at EMBL in the lab of Ulrich Ruther
1987-1989: Postdoctoral researcher with Frank Gannon, University of Galway, Ireland
Education
1983-1987: Ph.D. in Pharmacology, University College Dublin, Ireland
1978-1982: B.Sc. Pharmacology, University College Dublin, Ireland
Administration
Establishment of confocal microscopy facility at UOI/ BRI-FORTH, Greece (2001)
Establishment/Head of super-resolution microscopy at BRI-FORTH, Greece (2010-2018)
Establishment of hESC and hiPSC unit in BRI-FORTH, Ioannina, Greece (2010- present)
Establishment of hESC and hiPSC unit in University of Birmingham (UoB), UK (2015-2017)
Interdepartmental Committee Member of the Masters in Mol Cell Biol & Biotech, University of Ioannina (2018-2021)
Member of Bioimaging Greece (2017-present)
Director of Birmingham Light Microscopy Facility, UoB, UK (2015-2017)
Imaging Lead for UoB, UK, IMPACT PhD studentship Program (2015-2017)
Lecturer and participating PI in The Wellcome Trust Doctoral Training, MIDAS (2015-2017)
Management Board Member and participating PI in COMPARE network (2015-2017)
Participating PI in "The Midlands Integrative Biosciences Training Partnership" (2015-2017)
Head of ESI committee of BRI, FORTH, Ioannina 2022-2025
Reviewing Activities
Reviewer for several international scientific journals: <i>Oncogene</i> , <i>Journal Cell Science</i> , <i>BMC Developmental Biology</i> , <i>Cell Motility and Cytoskeleton</i> , <i>FEBS Journal</i> , <i>Plos One</i> , <i>Proteomics</i> , <i>Molecular Biology of the Cell</i> , <i>Cellular and Molecular Biology Letters</i> , <i>Scientific reports</i> , <i>BMC Cell Biology</i>
Editorial board member of <i>Scientific Reports</i> .
Reviewer for European Union 2019-present.

Teaching Activities
1997- present Supervisor of undergraduate, Masters and PhD theses in BRI-FORTH
1997- present Supervisor of PhD students in Biotechnology, Interdepartmental postgraduate program (Medicine, Chemistry and Biological Applications and Technologies)

<p>2015-2017 Undergraduate & Postgraduate Biosciences teaching in University of Birmingham:</p> <ol style="list-style-type: none"> (1) <i>Membrane structure and function</i> (2) <i>Secretory Pathway and exocytosis</i> (3) <i>Cytoskeleton</i> (4) <i>Endocytosis and endocytic trafficking</i> (5) <i>Stem cell biology</i> (6) <i>Calcium entry and exit</i> (7) <i>IP3Rs/ Ryanodine receptors</i> (8) <i>Autophagy</i> (9) <i>Angiogenesis/Vasculogenesis</i> <p>2015-2017 Lecturer and participating PI in The Wellcome Trust Doctoral Training, MIDAS</p> <ol style="list-style-type: none"> (1) <i>Membrane dynamics in the endocytic pathway : relation to signalling and perspectives in stem cell biology</i> (2) <i>Stem Cells</i>
<p>2015- 2017 Supervisor of undergraduate, Masters & PhD theses University of Birmingham</p>
<p>2015-present Teacher and Supervisor of Masters project students in the Master's Programme: Molecular Cell Biology and Biotechnology, UOI and BRI-FORTH, Ioannina.</p>
<p>2017-present Vice Head of Stem Cell teaching of Master's Programme: Molecular Cell Biology and Biotechnology, UOI and BRI-FORTH, Ioannina. Teaching as follows:</p> <ol style="list-style-type: none"> (1) <i>Introduction to CRISPR</i> (2) <i>Reprogramming</i> (3) <i>Transdifferentiation</i> (4) <i>Stem cell niche</i> (5) <i>Stem cell differentiation and organ development</i>
<p>2022-present External collaborator at European University Cyprus, Regenerative Medicine course. Teaching:</p> <ol style="list-style-type: none"> (1) <i>Introduction to Stem Cells</i> (2) <i>Cell Reprogramming/Cell Transplantation</i> (3) <i>Therapeutic uses of Stem Cells</i> (4) <i>Neurogenesis</i> (5) <i>Organoids</i>
<p>Research Grants</p>
<p>As Principal Investigator or work-package leader</p>
<p>1996-1997 Senior researcher award from the EU: 54,500 ECU.</p>
<p>2000-2002 FP5 ETN project. Membrane-cytoskeleton interactions in intracellular transport and cell morphogenesis. Coordinator: Marino Zerial. Responsible for the Ioannina group: C. Murphy. Total budget: 1.470.000 €. BRI-FORTH: 180,000 €.</p>
<p>2004-2005 GSRT. Applications of light microscopy in biomedical research and diagnosis. Principal investigator: Ch. Boleti, Pasteur Institute, Athens. Responsible for the Ioannina group: C. Murphy. Total budget: 180,000 €. BRI-FORTH: 37,153 €.</p>
<p>2006-2010 GRST PENED 2003/03ED688. Investigation of the role of Rho GTPases in the regulation of the genomic and non-genomic responses of cells to cytokines. Coordinator: C. Stournaras, University of Crete, Responsible for the Ioannina group: C. Murphy. Total budget: 180,000 €. BBRI-FORTH: 44, 625 €</p>
<p>2006-2010 FP6. EndoTrack LSH-2004-1.1.5-2: Tracking the Endocytic Routes of Polypeptide Growth Factor Receptor Complexes and their Modulatory Role on Signalling</p>

(EndoTrack). Coordinator: Marino Zerial. Responsible in Ioannina: C. Murphy. Total budget: 10,864,508 €. BRI-FORTH 883,000 €
2007-2013 NSRF. NoisePlus. Mechanisms of Induced Pluripotency: From Transcriptional Noise to Stem Cell Therapies. Coordinator: D. Thanos. Responsible in Ioannina: S. Georgatos. Work package C. Murphy: reprogramming human somatic cells to pluripotency. Total budget: 1.680.000 €. BRI-FORTH 444,500 €
2011-2015 NSRF. StemCycle. Stem Cycle Variations: Comparing the Stem Cell and Cancer Cell Life Cycles. Coordinator: Zoi Lygerou. Responsible in Ioannina: C. Murphy. Budget: 600.000 €. BRI-FORTH 88,500 €.
2011-2015 NSRF. “Remodeling Diabetic and Ischemic Retinal Vasculature Using Progenitor Stem Cells”. Acronym: ReVaReSC. Postdoctoral Researcher: Eleni Bagli. Host Institute: BRI-FORTH. Scientific Responsible: C. Murphy, T. Fotsis. Budget: 150.000 €.
2015-2017: GSRT. Kripis I: Biology, Biophotonics, and Health: Modern technological approaches and applications in the field of Biology, Photonics and Health. Research program for the development of research institutes. Budget 6.000 €.
2015-2017 University of Birmingham. Role of trafficking and signalling in stem cells. £100.000
2016-2017 The Centre of Membrane Proteins and Receptors (COMPARE) award: Elucidating Activin A/Receptor complex trafficking and signalling: Link to cell differentiation. £25,000. Contract Number: DLABGBI1270.
2019-2021: Human Resource Development, Education and Lifetime Learning. ESPA 2014-2020 co-financing of Greece/European Union. Title: Creation of distinct types of Mural Cells by the differentiation of human pluripotent stem cells and their application in vascularised tissue constructs. Principal Investigator: C. Murphy; Budget 45,500 €.
2020-2023: Unified Action of State Aid for Technology Research Development and Innovation "RESEARCH - CREATE – INNOVATE. ESPA. Title: Development of novel therapeutic strategies against Parkinsons disease. Coordinator: G. Garinis. Responsible in Ioannina: Murphy/Gkogkas. Budget: 1.000.000 €. BRI-FORTH 200.000 €. Contract number: MIS 5095050
2022-2025: ELIDEK PhD student fellowship. Human vascular organoids as a model system to study retinal diseases. Budget: 32,400 E. Contract number: 06498.
As key collaborator and/or CO-PI
1998-2001 EPET II, GSRT (97EKBAN2-1.1-20). Early inhibition of sepsis: Development of intervention methods in the molecular mechanism of signal transduction. Coordinator: C. Roussos, Assistant coordinator and principal investigator of the Ioannina team: T. Fotsis. Budget: 880.411 €. BRI-FORTH: 181, 951 €.
2001-2004 FP5 - QLK1-2000-00266. The role of dietary phytoestrogens in the prevention of breast and prostate cancer. Coordinator: Ian Rowland. Principal investigator of the University of Ioannina team: T. Fotsis. Budget: 2.660.430 €. BRI-FORTH: 247,800 €.
2001-2004 FP5 - QLG1-CT-2001-01032. Targeting of angiogenic TGFbeta signalling in cancer and cardiovascular diseases. Coordinator: T. Fotsis. Responsible for the Ioannina team: T. Fotsis. Budget: 1.571.728 €. BRI-FORTH: 284, 196 €.
2003-2007 GSRT, PENED 2001/01EΔ585. Signal transduction and intracellular membrane trafficking in endothelial cell. Principal investigator: T. Fotsis. Budget: 132 062 €.
2005-2008 Ministry of Education, Pythagoras II programme. The role of lipid rafts and caveolae in thrombosis and angiogenesis. Principal investigator: T. Fotsis. Budget: 50.000 €.
2006-2010 FP6 LSHM-CT-2006-018725. Pulmotension. Pulmonary Hypertension: Functional Genomics and Therapy of Lung Vascular Remodelling. Coordinator: W. Seeger. Responsible in Ioannina: S. Christoforidis. Budget: 11.400.00 €. BRI-FORTH 240.045 €

2007-2013 NSRF. “Education and Lifelong Learning” program “Supporting Postdoctoral Researchers”. Title: Bone Regeneration Using Keratin-Based Biomaterials And Mesenchymal Stem Cells. Scientific Responsible: T. Fotsis. Budget: 150.000 €.
2012-2015 NSRF. AdiSC. Title: Role and Mechanisms of Asymmetric Cell Division in Stem Cell Differentiation. Coordinator: T. Fotsis. Budget: 600.000 €. BRI-FORTH: 200,000 €.
2013-2015 NSRF: POM “PIK3CA Oncogenic Mutations in Breast and Colon Cancers: Development of Targeted Anticancer Drugs and Diagnostics”. Coordinator: A. Efstratiadis, GD-BRFAA. Responsible for the Ioannina team: T. Fotsis. Budget: 1.962.900 €. BRI-FORTH 189.000 €
2018-2021 Integrated Environmental Management (2.1); Title: Promoting Silver tourism through valorization of MED-diet and wellbeing routes in the CBC area; Acronym: Silver wellbeing Funding Source: Hellenic Ministry of Finance and Development & Tourism; Type of Grant: PA 2014-2020/Interreg Greece-Italy/2. Budget: 891.999,12 €. Principal Investigator for BRI-FORTH: T. Fotsis; Budget for BRI-FORTH: 158.619,25 €
2020-2022 FORTH SYNERGY GRANT. Title: Modelling neurological disorders using graphene-based neurovascular organoids derived from pluripotent human cells. Funding Source: FORTH Inter-Institutional Interdisciplinary award. Budget: 60,000 €. Co-ordinator: C. Gkogkas, BRI-FORTH, Ioannina. Co-PIs: C. Murphy, BRI-FORTH, Ioannina and G. Deligeorgis, IESL, FORTH, Heraklion, Crete.
2024-2026 ELIDEK Basic Research Financing Action. Title: Molecular Mechanisms of Vessel Morphogenesis – MorphoVess. Funding Source: Hellenic Foundation for Research and Innovation. Budget: Co-ordinator: Carol Murphy. Collaborating-PI Periklis Papadopoulos. Total budget 400,000E.

Publication record
Number of scientific publications 54 . Total citations: 5080. H Factor 31. ORCHID ID: 0000-0003-1353-8558. https://scholar.google.com/citations?hl=el&user=U0ioQy8AAAAJ .

Karydis-Messinis A, Moschovas D, Markou M, Gkantzou E, Vasileiadis V, Tsirka K, Gioti C, Vasilopoulos KC, Bagli E, Murphy C, Salmas CE, Giannakas AE, Hatziloukas E, Stamatis H, Paipetis A, Karakassides MA, Avgeropoulos A, Zafeiropoulos NE: Development, physicochemical characterization and in vitro evaluation of chitosan-fish gelatin-glycerol hydrogel membranes for wound treatment applications. <i>Carbohydrate Polymer Technologies and Applications</i> 6 (2023) 100338. https://www.sciencedirect.com/science/article/pii/S2666893923000592
Karydis-Messinis A, Moschovas D, Markou M, Tsirka K, Gioti C, Bagli E, Murphy C, Giannakas AE, Paitetis A, Karakassides MA, Avgeropoulos A, Salmas CE, Zafeiropoulos NE: Hydrogel Membranes from Chitosan-Fish Gelatin-Glycerol for Biomedical Applications: Chondroitin Sulfate Incorporation Effect in Membrane Properties. <i>Gels</i> 2023, 9, 844. https://doi.org/10.3390/gels9110844 .
Chalkiadaki K, Statoulla E, Markou M, Bellou S, Bagkli E, Fotsis T, Murphy C , Gkogkas C.: Translational control in neurovascular brain development. <i>R. Soc. Open Sci.</i> 8: 211088. https://doi.org/10.1098/rsos.211088 .
Kostopoulou N, Bellou S, Bagli E, Markou M, Kostaras E, Hyvönen M, Kalaidzidis Y, Angelos Papadopoulos A, Chalmantzi V, Kyrkou A, Panopoulou E, Fotsis T, Murphy C : Embryonic Stem Cells Are Devoid of Macropinocytosis, a Trafficking Pathway for Activin A in Differentiated

- Cells. *J. Cell Sci.* 2021 Jul 1;134(13):jcs246892. doi: 10.1242/jcs.246892. Epub 2021 Jul 12. <https://pubmed.ncbi.nlm.nih.gov/34313314/>
- Chalmantzi V, Simitzi C, Papadopoulos A, Bagli E, **Murphy C**, Stratakis E, Fotsis T: Culturing human pluripotent stem cells on micropatterned silicon surfaces. In: *Methods in Molecular Biology*. Springer, New York, NY. doi.org/10.1007/7651_2021_428. Dec. 2021.
- Kougioumtzi A, Chatziathanasiadou M, Vrettos EI, Sayyad N, Sakka M, Stathopoulos P, Mantzaris MD, Ganai M, Karpoormath R, Vartholomatos G, Tsikaris V, Lazarides T, **Murphy C**, Tzakos AG: Development of novel GnRH and Tat⁴⁸⁻⁶⁰ based luminescent agents with enhanced cellular uptake and bioimaging properties. *Dalton Transactions*, issue 26, 2021, <https://pubs.rsc.org/en/content/articlelanding/2021/dt/d1dt00060h>
- Markou M, Kouroupis D, Fotsis T, Bagli E, **Murphy C**. Vascularisation in 3D cell culture. *Basic Concepts on 3D Cell culture*. Springer. ISBN 978-3-030-66749-8. 2021. <https://doi.org/10.1007/978-3-030-66749-8>
- Vrettos E, Karampelas T., Sayyad N, Kougioumtzi A, Syed N, Crook T, **Murphy C**, Tamvakopoulos C, Tzakos A: Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable “click” oxime bond tethers and preclinical evaluation against prostate cancer. *Eur. J. Medicinal Chem.* 211(2021)113018. <https://pubmed.ncbi.nlm.nih.gov/33223264/>
- Papadopoulos A, Chalmantzi V, Mikhaylichenko O, Hyvönen M, Stellas D, Kanhere A, Heath J, Cunningham DL, Fotsis T, **Murphy C**: Supporting data on combined transcriptomics and phosphoproteomic analysis of BMP4 signaling in human embryonic stem cells. *Data in Brief* 35 (2021) 106844. <https://www.sciencedirect.com/science/article/pii/S2352340921001281>
- Papadopoulos A, Chalmantzi V, Mikhaylichenko O, Hyvönen M, Stellas D, Kanhere A, Heath J, Cunningham DL, Fotsis T, **Murphy C**: Combined transcriptomics and phosphoproteomic analysis of BMP4 signaling in human embryonic stem cells. *Stem Cell Res* 50 (2021) 102133. <https://pubmed.ncbi.nlm.nih.gov/33383406/>
- Markou M, Kouroupis D, Badounas F, Katsouras A, Kyrkou A, Fotsis T, **Murphy C***, Bagli E*. Tissue engineering using vascular organoids from human pluripotent stem cell derived mural cell phenotypes. *Front Bioeng Biotechnol*, section Tissue Engineering and Regenerative Medicine. 8(2020) article 278, 1-20.* joint corresponding authors. <https://pubmed.ncbi.nlm.nih.gov/32363181/>
- Basagiannis D, Zografou S, **Murphy C**, Fotsis T, Morbidelli L, Ziche M, Bleck C, Mercer J, Christoforidis S. VEGF induces signalling and angiogenesis by directing VEGFR2 internalisation via macropinocytosis. *J. Cell Sci* 129 (2016) 4091-4104. <https://www.ncbi.nlm.nih.gov/pubmed/27656109>
- Tsolis K, Bagli E, Kanaki K, Zografou S, Carpentier S, Bei E, Christoforidis S, Zervakis M, **Murphy C**, Fotsis T, Economou A. Proteome changes during transition from human embryonic to vascular progenitor cells. *J Proteome Res* 15 (2016) 1995-2007. <https://www.ncbi.nlm.nih.gov/pubmed/27146950>
- Kyrkou A, Stellas D, Syrrou M, Klinakis A, Fotsis T, **Murphy C**: Generation of human induced pluripotent stem cells in defined, feeder-free conditions. *Stem Cell Res*, 17 (2016) 458-460. <https://www.sciencedirect.com/science/article/pii/S1873506116300381>
- Kouroupis D, Kyrkou A, Triantafyllidi E, Katsimpoulas M, Chalepakis G, Goussia A, Georgoulis A, **Murphy C**, Fotsis T: Generation of stem cell-based bioartificial anterior cruciate ligament (ACL) grafts for effective ACL rupture repair. *Stem Cell Res* 17 (2016) 448-457. <https://www.ncbi.nlm.nih.gov/pubmed/27217303>
- Karali E, Bellou S, Stellas D, Klinakis A, **Murphy C**, Fotsis T: VEGF signaling, mTOR complexes, and the endoplasmic reticulum: Towards a role of metabolic sensing in the regulation of angiogenesis. *Mol and Cell Oncol.* 1:3, e964024, <https://pubmed.ncbi.nlm.nih.gov/27308350/>.
- Karali E, Bellou S, Stellas D, Klinakis A, **Murphy C**, Fotsis T: ER mediates induction of endothelial cell survival and angiogenesis by VEGF: PLCg via mTORC1 activates ATF6 and PERK. *Mol. Cell* 54 (2014) 559-72. <https://www.ncbi.nlm.nih.gov/pubmed/24746698>
- Kostaras E, Pedersen NM, Stenmark H, Fotsis T, **Murphy C**: SARA and RNF11 at the crossroads of EGFR signalling and trafficking. *Methods Enzymol* 535 (2014) 225-47. <https://www.ncbi.nlm.nih.gov/pubmed/24377927>

- Bellou S, Pentheroudakis G, **Murphy C**, Fotsis T: Anti-angiogenesis in cancer therapy: Hercules and Hydra. *Cancer Lett.* 338 (2013) 291-28. <https://www.ncbi.nlm.nih.gov/pubmed/23707856>
- Kyrkou A, Soufi M, Bahtz R, Ferguson C, Bai M, Parton RG, Hoffmann I, Zerial M, Fotsis T, **Murphy C**: RhoD participates in the regulation of cell-cycle progression and centrosome duplication. *Oncogene* 2013, 32:1831-1842. <https://www.ncbi.nlm.nih.gov/pubmed/22665057>
- Kyrkou A, Soufi M, Bahtz R, Ferguson C, Bai M, Parton RG, Hoffmann I, Zerial M, Fotsis T, **Murphy C**: The RhoD to centrosomal duplication. *Small GTPases* 2013, 4. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747252/>
- Kostaras E, Sflomos G, Pedersen NM, Stenmark H, Fotsis T, **Murphy C**: SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking. *Oncogene* 32 (2013) 5220-32. <https://www.ncbi.nlm.nih.gov/pubmed/23222715>
- Bellou S, Karali E, Bagli E, Al-Maharik N, Morbidelli L, Ziche M, Adlercreutz H, **Murphy C**, Fotsis T: The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth. *Mol Cancer* 2012, 11:35. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3406996/>
- Sflomos G, Kostaras E, Panopoulou E, Pappas N, Kyrkou A, Politou AS, Fotsis T, **Murphy C**: ERBIN is a new SARA-interacting protein: competition between SARA and SMAD2 and SMAD3 for binding to ERBIN. *J Cell Sci* 2011, 124:3209-3222. <https://www.ncbi.nlm.nih.gov/pubmed/21878490>
- Bellou S, Hink MA, Bagli E, Panopoulou E, Bastiaens PI, **Murphy C**, Fotsis T: VEGF autoregulates its proliferative and migratory ERK1/2 and p38 cascades by enhancing the expression of DUSP1 and DUSP5 phosphatases in endothelial cells. *Am J Physiol Cell Physiol* 2009, 297:C1477-1489. <https://www.ncbi.nlm.nih.gov/pubmed/19741200>
- Kardassis D, **Murphy C**, Fotsis T, Moustakas A, Stournaras C: Control of transforming growth factor beta signal transduction by small GTPases. *FEBS J* 2009, 276:2947-2965. <https://www.ncbi.nlm.nih.gov/pubmed/19490100>
- Murphy C**: Endo-fin-ally a SARA for BMP receptors. *J Cell Sci* 2007, 120:1153-1155. <https://pubmed.ncbi.nlm.nih.gov/17376961/>
- Fyhrquist P, Mwasumbi L, Vuorela P, Vuorela H, Hiltunen R, **Murphy C**, Adlercreutz H: Preliminary antiproliferative effects of some species of Terminalia, Combretum and Pteleopsis collected in Tanzania on some human cancer cell lines. *Fitoterapia* 2006, 77:358-366. <https://www.ncbi.nlm.nih.gov/pubmed/16797142>
- Papanikolaou A, Papafotika A, **Murphy C**, Papamarcaki T, Tsolas O, Drab M, Kurzchalia TV, Kasper M, Christoforidis S: Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. *J Biol Chem* 2005, 280:26406-26414. <https://www.ncbi.nlm.nih.gov/pubmed/15890655>
- Panopoulou E, **Murphy C**, Rasmussen H, Bagli E, Rofstad EK, Fotsis T: Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. *Cancer Res* 2005, 65:1877-1886. <https://www.ncbi.nlm.nih.gov/pubmed/15753386>
- Bagli E, Stefanidou M, Morbidelli L, Ziche M, Psillas K, **Murphy C**, Fotsis T: Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. *Cancer Res* 2004, 64:7936-7946. <https://www.ncbi.nlm.nih.gov/pubmed/15520200>
- Bagli E., Xagorari A., Papetropoulos A, **Murphy C**, Fotsis T: Angiogenesis in inflammation. *Autoimmunity reviews* 2004 3 Suppl 1:S26. <https://pubmed.ncbi.nlm.nih.gov/15309776/>
- Panopoulou E, Gillooly DJ, Wrana JL, Zerial M, Stenmark H, **Murphy C***, Fotsis T*: Early endosomal regulation of Smad-dependent signalling in endothelial cells. *J Biol Chem* 2002, 277:18046-18052. * joint last authors. <https://www.ncbi.nlm.nih.gov/pubmed/11877415>
- Karetsou Z, Kretsovali A, **Murphy C**, Tsolas O, Papamarcaki T: Prothymosin alpha interacts with the CREB-binding protein and potentiates transcription. *EMBO Rep* 2002, 3:361-366. <https://www.ncbi.nlm.nih.gov/pubmed/11897665>
- Hatzi E, **Murphy C**, Zoepfel A, Rasmussen H, Morbidelli L, Ahorn H, Kunisada K, Tontsch U, Klenk M, Yamauchi-Takahara K, et al.: N-myc oncogene overexpression down-regulates IL-6;

- evidence that IL-6 inhibits angiogenesis and suppresses neuroblastoma tumor growth. *Oncogene* 2002, 21:3552-3561. <https://www.ncbi.nlm.nih.gov/pubmed/12032857>
- Hatzi E, **Murphy C**, Zoepfel A, Ahorn H, Tontsch U, Bamberger AM, Yamauchi-Takahara K, Schweigerer L, Fotsis T: N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma. *Eur J Biochem* 2002, 269:3732-3741. <https://www.ncbi.nlm.nih.gov/pubmed/12153570>
- Murphy C**, Saffrich R, Olivo-Marin JC, Giner A, Ansoerge W, Fotsis T, Zerial M: Dual function of rhoD in vesicular movement and cell motility. *Eur J Cell Biol* 2001, 80:391-398. <https://www.ncbi.nlm.nih.gov/pubmed/11484930>
- Hatzi E, Breit S, Zoepfel A, Ashman K, Tontsch U, Ahorn H, **Murphy C**, Schweigerer L, Fotsis T: MYCN oncogene and angiogenesis: down-regulation of endothelial growth inhibitors in human neuroblastoma cells. Purification, structural, and functional characterization. *Adv Exp Med Biol* 2000, 476:239-248. <https://pubmed.ncbi.nlm.nih.gov/10949669/>
- Pappas P, Stephanou P, Sotiropoulou M, **Murphy C**, Salminen L, Marselos M: Effects of tamoxifen and toremifene on ALDH1 and ALDH3 in human retinal pigment epithelial cells and rat liver. *Adv Exp Med Biol* 1999, 463:151-158. <https://pubmed.ncbi.nlm.nih.gov/10352680/>
- McBride HM, Rybin V, **Murphy C**, Giner A, Teasdale R, Zerial M: Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13. *Cell* 1999, 98:377-386. <https://pubmed.ncbi.nlm.nih.gov/10458612/>
- Zacchi P, Stenmark H, Parton RG, Orioli D, Lim F, Giner A, Mellman I, Zerial M, **Murphy C**: Rab17 regulates membrane trafficking through apical recycling endosomes in polarized epithelial cells. *J Cell Biol* 1998, 140:1039-1053. <https://pubmed.ncbi.nlm.nih.gov/9490718/>
- Simonsen A, Lippe R, Christoforidis S, Gaullier JM, Brech A, Callaghan J, Toh BH, **Murphy C**, Zerial M, Stenmark H: EEA1 links PI(3)K function to Rab5 regulation of endosome fusion. *Nature* 1998, 394:494-498. <https://pubmed.ncbi.nlm.nih.gov/9697774/>
- Murphy C**, Zacchi P, Parton RG, Zerial M, Lim F: HSV infection of polarized epithelial cells on filter supports: implications for transport assays and protein localization. *Eur J Cell Biol* 1997, 72:278-281. <https://pubmed.ncbi.nlm.nih.gov/9084990/>
- Zuniga Mejia Borja A, **Murphy C**, Zeller R: AltFGF-2, a novel ER-associated FGF-2 protein isoform: its embryonic distribution and functional analysis during neural tube development. *Dev Biol* 1996, 180:680-692. <https://pubmed.ncbi.nlm.nih.gov/8954736/>
- Murphy C**, Saffrich R, Grummt M, Gournier H, Rybin V, Rubino M, Auvinen P, Lutcke A, Parton RG, Zerial M: Endosome dynamics regulated by a Rho protein. *Nature* 1996, 384:427-432. <https://pubmed.ncbi.nlm.nih.gov/8945468/>
- Kretschmer C*, **Murphy C***, Biesinger B, Beckers J, Fickenscher H, Kirchner T, Fleckenstein B, Ruther U: A Herpes saimiri oncogene causing peripheral T-cell lymphoma in transgenic mice. *Oncogene* 1996, 12:1609-1616.* joint first authors. <https://pubmed.ncbi.nlm.nih.gov/8622880/>
- Murphy C**, Zerial M: Expression of Rab proteins during mouse embryonic development. *Methods Enzymol* 1995, 257:324-332. <https://pubmed.ncbi.nlm.nih.gov/8583936/>
- Murphy C**, Beckers J, Ruther U: Regulation of the human C-reactive protein gene in transgenic mice. *J Biol Chem* 1995, 270:704-708. <https://pubmed.ncbi.nlm.nih.gov/7822299/>
- Murphy C**, Kretschmer C, Biesinger B, Beckers J, Jung J, Desrosiers RC, Muller-Hermelink HK, Fleckenstein BW, Ruther U: Epithelial tumours induced by a herpesvirus oncogene in transgenic mice. *Oncogene* 1994, 9:221-226. <https://pubmed.ncbi.nlm.nih.gov/8302583/>
- Lutcke A, Parton RG, **Murphy C**, Olkkonen VM, Dupree P, Valencia A, Simons K, Zerial M: Cloning and subcellular localization of novel rab proteins reveals polarized and cell type-specific expression. *J Cell Sci* 1994, 107 (Pt 12):3437-3448. <https://pubmed.ncbi.nlm.nih.gov/7706395/>
- Fotsis T, **Murphy C**, Gannon F: Nucleotide sequence of the bovine insulin-like growth factor 1 (IGF-1) and its IGF-1A precursor. *Nucleic Acids Res* 1990, 18:676. <https://pubmed.ncbi.nlm.nih.gov/2308858/>
- Murphy C**, Fotsis T, Pantzar P, Adlercreutz H, Martin F: Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). *J Steroid Biochem Mol Biol* 1987, 26:547-555. <https://pubmed.ncbi.nlm.nih.gov/3586671/>

Murphy C, Fotsis T, Pantzar P, Adlercreutz H, Martin F: Analysis of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen levels in cytosol and KCl-nuclear extracts of breast tumours from tamoxifen treated patients by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). *J Steroid Biochem Mol Biol* 1987, 28:609-618. <https://pubmed.ncbi.nlm.nih.gov/3695512/>

Murphy C, Fotsis T, Adlercreutz H, Martin F: Analysis of tamoxifen and 4-hydroxytamoxifen levels in immature rat uterine cytoplasm and KCl-nuclear extracts by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM). *J Steroid Biochem Mol Biol* 1987, 28:289-299. <https://pubmed.ncbi.nlm.nih.gov/3657151/>